Effect of Tanreqing injection on mycoplasma pneumonia in patients of hs-CRP, PCT, T cell subsets

摘要

Objective: To explore the effect of Tanreqing injection for treatment and its clinical significance through the changes of mycoplasma pneumonia patients with hs-CRP, PCT levels and cellular immune index. Method:A total of 114 cases of mycoplasma pneumonia, which were randomly divided into routine antibiotic treatment group (n=53) (control group), Tanreqing injection treatment group (n=61) (treatment group), to observe the two groups' hs-CRP and PCT levels in serum and the cellular immune regulation after treatment in patients, and contrast the curative effect. Results:the two groups before treatment, hs-CRP and PCT levels in serum had no significant difference;the treatment group after treatment, hs-CRP and PCT levels in serum were significantly lower than before treatment, and lower than that of the control group's;the control group after treatment of serum hs-CRP was significantly lower than that before treatment, compared to the before treatment, the level of PCT decreased slightly, but compared with before treatment there was no significant difference;after treatment, CD3+, CD4+, CD4+/CD8+, CD56+value were significantly higher than the control group's;CD8+and CD4+CD25+were significantly lower than the control group's;effective treatment group was significantly higher than the control group. The average hospitalization time was less than the control group's. Conclusion:Tanreqing injection adjuvant therapy could improve the treatment effect in mycoplasma pneumonia patients, regulate immune function, which was worth popularizing in clinical use.